Natco Pharma Q2 profit declines to Rs 118 crore due to drop in oseltamivir product sales in US

"The decline in revenues and profits compared to the same period last year is primarily due to the anticipated drop in oseltamivir product sales in the US and Hep C sales in India," Natco Pharma said.

New Delhi: Natco Pharma on Tuesday reported a 35 per cent decline in consolidated net profit at Rs 117.7 crore for the quarter ended September 30, 2019.

The Hyderabad-based company had posted a profit of Rs 181.1 crore in the year-ago period, Natco Pharma said in a BSE filing.

Total income stood at Rs 518.9 crore for the quarter under review as against Rs 583.5 crore in the year-ago period, a decline of 11 per cent, it added.

Read Also: Natco Pharma Mekaguda facility gets EIR from USFDA

"The decline in revenues and profits compared to the same period last year is primarily due to the anticipated drop in oseltamivir product sales in the US and Hep C sales in India," Natco Pharma said.

The company's board has recommended an interim dividend of Re 1 per equity share of Rs 2 each for the financial year 2019-20, it added

Read Also: Fight for Vildagliptin: Natco goes to court against Novartis